High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients

Berrie Meijer, Margien L. Seinen, Tessa Hosman, Ronald K. Linskens, Jan-Kees Kneppelhout, Godefridus J. Peters, Chris J. J. Mulder, Adriaan A. van Bodegraven, Nanne K. H. de Boer

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: Thiopurines play an essential role in the management of inflammatory bowel diseases (IBD, i.e. Crohn's disease and ulcerative colitis). Over the past decade, several strategies to optimize treatment with thiopurines have been evaluated, including co-administration of allopurinol, a xanthine-oxidoreductase (XO) inhibitor, to low-dose thiopurine therapy. We aimed to assess the inter-individual variability of XO-activity between IBD-patients. Methods: We assessed XO activity in serum of IBD-patients of two medical centers in The Netherlands using the Amplex® Red Xanthine/Xanthine Oxidase Assay Kit, which measures the superoxide formation in a coupled reaction to the red-fluorescent oxidation product, resofurine. Results: We observed a high inter-individual variability of XO-activity in 119 patients, with a median activity of 16 µU/ml/hour (range 1–85 µU/ml/hour). The XO-activity was influenced by gender (male 19.5 vs. female 14.0 µU/ml/hour, p < 0.01), patient's age (Pearson's correlation r = 0.21, p = 0.02) and duration of IBD (r = 0.23, p = 0.01). The XO activity was not affected by the type of IBD, smoking status, body mass index or (type of) thiopurine use (p > 0.05). Conclusions: There is a high inter-individual variability of XO-activity in IBD-patients; XO-activity is positively associated with male gender and patient's age.
Original languageEnglish
Pages (from-to)317-323
JournalNucleosides, Nucleotides and Nucleic Acids
Volume37
Issue number6
DOIs
Publication statusPublished - 2018

Cite this